Name: Latest research reports of Ajanta Pharma Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Ajanta Pharma Ltd.
Rating: 1
Author: BOB Capital Markets Ltd.

Ajanta Pharma Ltd.

NSE: AJANTPHARM | BSE: 532331 | ISIN: INE031B01049 | Industry: Pharmaceuticals
| Mid-range Performer

2680.9000 -25.50 (-0.94%)

NSE Jan 16, 2026 15:31 PM

Volume: 61,632

Ajanta Pharma Ltd.

11 Dec 2024

2680.90

-0.94%

Ajanta Pharma (SELL): No incremental triggers; valuation expensive

Sell: Ajanta Pharma Ltd.

Recommendation Target

BOB Capital Markets Ltd.

At our virtual conference AJP said it is not looking to venture into newer therapies in India in the next 1-2 years due to hefty valuations

Number of FII/FPI investors decreased from 343 to 316 in Dec 2025 qtr